Time to diagnosis, the interval that passes from first symptom presentation until diagnosis, varies by cancer type among children, adolescents, and young adults and may be affected by clinical and sociodemogrpahic factors.
Time to diagnosis among children, adolescents, and young adults (AYAs) varies by cancer type and may be affected by clinical and sociodemographic factors, according to an abstract presented at the 2019 American Society of Clinical Oncology Annual Meeting, held May 31 to June 4, 2019, in Chicago, Illinois.
Researchers used claims data for commercially insured enrollees in a large United States health plan from OptumLabs Data Warehouse. They identified pediatric patients 14 years and younger, as well as AYAs 15 to 39 years old diagnosed with soft tissue sarcomas (STS), bone tumors (BT), and germ cell tumors (GCT) during 2001 to 2017 who were continuously enrolled for 6 months prior to being diagnosed.
Time to diagnosis was calculated as the number of days between a patient’s first medical encounter associated with a potential cancer symptom and their diagnosis date. Researchers compared median times from first symptom to diagnosis using the Wilcoxon Rank Sum test. They used multivariable logistic regression to identify sociodemographic and clinical factors associated with intervals longer than 3 months from appearance of symptoms to diagnosis.
Of 11,395 total patients, 86% presented to medical care with symptoms before they were diagnosed. A total of 2228 patients had STS, 1565 patients had BT, and 5904 had GCT. The most common symptoms reported were pain and swelling.
Researchers found that:
Researchers determined there was a significant difference in median days to diagnosis by age:
There was not a significant difference in median days to diagnosis by age for STS.
Researchers also found that being from a household with a college degree or higher level of education, as well as seeing a specialist besides an oncologist when symptoms first appeared, was associated with a longer delay in diagnosis. Older age and being male were associated with a shorter delays in diagnosis.
“In a commercially insured population, time to diagnosis varies by cancer type and is impacted by clinical and sociodemographic factors,” researchers wrote. “Shorter time to diagnosis may represent delays in presenting to medical care or more acute presentations of symptoms, therefore patient-reported symptoms and barriers to care data should be collected to better define strategies to reduce delays in diagnosis."
Reference
Alvarez EM, Winestone L, McPheeters J, et al. Factors impacting time to diagnosis in pediatric, adolescent and young adult (AYA) patients with solid tumors. Presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, Illinois. Abstract e21515.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More